To determine the roles of genetic manipulation of LATS1/2 in the response of CML to IM treatment, LATS1/2—KD cells were treated with IM and the results were compared with those of their WT counterpart. This evidence concerns the gene LATS1 and chronic myelogenous leukemia, BCR-ABL1 positive.